Entegrion

Executive Summary

Entegrion is a life sciences company specializing in point-of-care blood coagulation monitoring. Its flagship product, the Viscoelastic Coagulation Monitor (VCM), is a portable, automated instrument that provides rapid, real-time hemostasis assessment using fresh whole blood. Designed for hospital, field, and veterinary settings, the VCM aims to improve clinical outcomes by enabling effective management of coagulopathies. Founded in 1983 and headquartered in Research Triangle Park, North Carolina, Entegrion has established a strong foundation in hemostasis diagnostics, though it remains privately held with limited public financial disclosure. The market for point-of-care coagulation testing is growing, driven by demand for rapid, decentralized diagnostics in trauma, surgery, and critical care. Entegrion's VCM is well-positioned to capture share from existing viscoelastic devices by offering portability and ease of use. Key near-term opportunities include expanding into the veterinary segment, where coagulation monitoring is an unmet need, and securing additional regulatory clearances for next-generation products. With a long operating history and a focused product strategy, Entegrion has the potential to gain traction in both human and animal health markets.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation VCM device70% success
• Q4 2026Commercial launch of VCM in the veterinary market60% success
• Q2 2026Strategic partnership with a major hospital network or distributor50% success